title: Natural killer and lymphokine-activated killer activity in HLA-B8,DR3-positive subjects.
abstract: The haplotype HLA-B8,DR3 is over-represented in several autoimmune diseases, implying that genes predisposing people to these disorders are linked to this haplotype. In these diseases, various dysfunctions reflecting an impairment of the immune system have been found. Several reports indicate also that in HLA-B8,DR3-positive healthy subjects similar disorders may be demonstrated. In the present work, we have evaluated NK and LAK activity in these subjects. The study has been performed on monocyte-depleted peripheral blood MNCs by using, the K-562 cell line as a target for NK activity and the HL-60 cell line for as a target LAK activity. LAK cells were obtained by incubating MNCs for 3 days with 100 U/ml of rIL-2. The results of our experiments demonstrate that NK cell activity is significantly decreased in healthy subjects bearing the HLA-B8,DR3 haplotype. Since the number of circulating CD16+ cells is not significantly different between HLA-B8,DR3-positive subjects and negative ones, it is unlikely that this defect is due to a decreased number of NK cells in effector cell preparations. The observation that the treatment with rIL-2 can restore the killer activity of MNCs from these subjects suggests instead that the reduced NK activity may be due at least in part to the imbalance of cytokine network that has been demonstrated in HLA-B8,DR3-positive subjects. Finally, since a decreased NK activity has been reported in the autoimmune diseases linked to this haplotype, our results support the suggestion that immunologic changes observed in autoimmune diseases reflect systemic regulatory disorders that have a genetic basis.
authors.affiliation: Institute of General Pathology, University of Palermo, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Caruso
authors.forename: G
authors.initials: G
authors.lastname: Candore
authors.forename: A T
authors.initials: AT
authors.lastname: Colucci
authors.forename: D
authors.initials: D
authors.lastname: Cigna
authors.forename: M A
authors.initials: MA
authors.lastname: Modica
authors.forename: G
authors.initials: G
authors.lastname: Tantillo
authors.forename: A
authors.initials: A
authors.lastname: Salerno
mesh_terms: D000328:Adult; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D005455:Fluorescent Antibody Technique; D015795:HLA-B8 Antigen / Q000502:physiology*; D015803:HLA-DR3 Antigen / Q000502:physiology*; D006239:Haplotypes; D006801:Humans; D007376:Interleukin-2 / Q000502:physiology; D015979:Killer Cells, Lymphokine-Activated / Q000502:physiology*; D007694:Killer Cells, Natural / Q000502:physiology*; D008297:Male; D017452:Receptors, IgG / Q000502:physiology; D014407:Tumor Cells, Cultured
chemical_list: D015795:HLA-B8 Antigen; D015803:HLA-DR3 Antigen; D007376:Interleukin-2; D017452:Receptors, IgG